4CPS-163 Bone metastasis treatment in prostate cancer: efficacy and safety

BackgroundProstate cancer most commonly metastasises to the bones, and preventing related complications is important. Denosumab and Zoledronic Acid are recommended to prevent skeletal-related events and malignant hypercalcaemia.PurposeThe aim of this study was to analyse the efficacy and safety of D...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A145-A145
Main Authors: Salmeron Navas, FJ, Martinez-Diaz, C, Camean-Castillo, M, Fenix-Caballero, S, Briceño-Casado, MP, Gil-Sierra, MD, Rios-Sanchez, E, Diaz-Navarro, J, Alegre-Del Rey, EJ, Borrero-Rubio, JM
Format: Article
Language:English
Subjects:
Metastasis
Monoclonal antibodies
Prostate cancer
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundProstate cancer most commonly metastasises to the bones, and preventing related complications is important. Denosumab and Zoledronic Acid are recommended to prevent skeletal-related events and malignant hypercalcaemia.PurposeThe aim of this study was to analyse the efficacy and safety of Denosumab and Zoledronic Acid for the treatment of metastatic prostate cancer.Material and methodsA retrospective observational study including patients with metastatic prostate cancer in treatment with Denosumab or Zoledronic Acid (ZA), from 1 January 2015 until 30 August 2018 was conducted. An electronic prescription oncology program and medical records were consulted. The variables recorded were age, administered drug, duration of treatment, calcium levels (baseline and final) and adverse events. Efficacy was assessed as absence of malignant hypercalcaemia defined as serum calcium of grade ≥2 by the Common Terminology Criteria of Adverse Events version 3.0 (serum calcium >11.5 mg/dl). Safety criteria were considered: treatment interruptions, grade-3 hypocalcaemia in final test (serum calcium
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2019-eahpconf.312